中国生物科技服务(08037.HK)披露新一代CD20靶向CAR-T进展
中国生物科技服务(08037.HK)就开展关於上海隆耀自主研发的新一代CD20靶向的自体CAR-T的研究者发起的临床研究进展显示,在临床前实验动物模型中,上海隆耀新一代CD20靶向CAR-T在小鼠体内显示出优异的抗肿瘤活性。
在肿瘤负荷控制,CAR-T细胞体内的扩增,都较临床广泛使用的二代CAR结果有显着提升,并且在性能提升的同时,未观察到CAR-T导致的毒副作用。
最新研究表明,CAR-T治疗淋巴瘤的有效性与回输细胞後CAR-T在体内扩增数量正相关。上海隆耀的新型CD20靶向CAR-T,在病人外周血中显示出超强的扩增能力。而上海隆耀所独有的信号传导结构和CAR结构设计都已经申请了国内专利和PCT专利,并都已经获得受理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.